The metabolic enzyme arginase-2 is a potential target for novel immune modulatory vaccines

ABSTRACT One way that tumors evade immune destruction is through tumor and stromal cell expression of arginine-degrading enzyme arginase-2 (ARG2). Here we describe the existence of pro-inflammatory effector T-cells that recognize ARG2 and can directly target tumor and tumor-infiltrating cells. Using a library of 34 peptides covering the entire ARG2 sequence, we examined reactivity toward these peptides in peripheral blood mononuclear cells from cancer patients and healthy individuals. Interferon-γ ELISPOT revealed frequent immune responses against several of the peptides, indicating that ARG2–specific self-reactive T-cells are natural components of the human T-cell repertoire. Based on this, the most immunogenic ARG2 protein region was further characterized. By identifying conditions in the microenvironment that induce ARG2 expression in myeloid cells, we showed that ARG2-specific CD4T-cells isolated and expanded from a peripheral pool from a prostate cancer patient could recognize target cells in an ARG2-dependent manner. In the ‘cold’ in vivo tumor model Lewis lung carcinoma, we found that activation of ARG2-specific T-cells by vaccination significantly inhibited tumor growth. Immune-modulatory vaccines targeting ARG2 thus are a candidate strategy for cancer immunotherapy.

[1]  I. Svane,et al.  Arginase-1-based vaccination against the tumor microenvironment: the identification of an optimal T-cell epitope , 2019, Cancer Immunology, Immunotherapy.

[2]  Ö. Met,et al.  Inflammation induced PD-L1-specific T cells , 2019, Cell stress.

[3]  N. Erez,et al.  The Dark Side of Fibroblasts: Cancer-Associated Fibroblasts as Mediators of Immunosuppression in the Tumor Microenvironment , 2019, Front. Immunol..

[4]  I. Svane,et al.  Peripheral memory T cells specific for Arginase-1 , 2019, Cellular & Molecular Immunology.

[5]  M. Andersen.  The targeting of tumor-associated macrophages by vaccination , 2019, Cell stress.

[6]  S. Burchill,et al.  Macrophage-Derived IL1β and TNFα Regulate Arginine Metabolism in Neuroblastoma. , 2018, Cancer research.

[7]  M. Andersen.  The Balance Players of the Adaptive Immune System. , 2018, Cancer research.

[8]  M. Donia,et al.  Frequent adaptive immune responses against arginase-1 , 2018, Oncoimmunology.

[9]  R. Bourgon,et al.  TGF-β attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells , 2018, Nature.

[10]  L. Grøntved,et al.  Tumor-Associated Macrophages Derived from Circulating Inflammatory Monocytes Degrade Collagen through Cellular Uptake. , 2017, Cell reports.

[11]  S. Bicciato,et al.  A Relay Pathway between Arginine and Tryptophan Metabolism Confers Immunosuppressive Properties on Dendritic Cells , 2017, Immunity.

[12]  Simon J. Dovedi,et al.  Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery , 2016, Cancer Immunology Research.

[13]  M. Donia,et al.  CCL22-specific T Cells: Modulating the immunosuppressive tumor microenvironment , 2016, Oncoimmunology.

[14]  M. Andersen.  Immune Regulation by Self-Recognition: Novel Possibilities for Anticancer Immunotherapy. , 2015, Journal of the National Cancer Institute.

[15]  R. Caldwell,et al.  Arginase: an old enzyme with new tricks. , 2015, Trends in pharmacological sciences.

[16]  P. Kearns,et al.  Arginine dependence of acute myeloid leukemia blast proliferation: a novel therapeutic target. , 2015, Blood.

[17]  Annie A Wu,et al.  Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells , 2015, Oncoimmunology.

[18]  J. Mes,et al.  THP-1 cell line: an in vitro cell model for immune modulation approach. , 2014, International immunopharmacology.

[19]  A. Epstein,et al.  Immunogenicity of Murine Solid Tumor Models as a Defining Feature of In Vivo Behavior and Response to Immunotherapy , 2013, Journal of immunotherapy.

[20]  P. Vyas,et al.  MYELOID NEOPLASIA Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment , 2022 .

[21]  A. Woetmann,et al.  Cutaneous T cell lymphoma cells are targets for immune checkpoint ligand PD-L1-specific, cytotoxic T cells , 2013, Leukemia.

[22]  I. Svane,et al.  The immune checkpoint regulator PD-L1 is a specific target for naturally occurring CD4+ T cells , 2013, Oncoimmunology.

[23]  M. Donia,et al.  HLA-restricted CTL that are specific for the immune checkpoint ligand PD-L1 occur with high frequency in cancer patients. , 2013, Cancer research.

[24]  D. Speiser,et al.  Prognostic value of arginase‐II expression and regulatory T‐cell infiltration in head and neck squamous cell carcinoma , 2013, International journal of cancer.

[25]  M. Donia,et al.  Natural CD4+ T-Cell Responses against Indoleamine 2,3-Dioxygenase , 2012, PloS one.

[26]  I. Svane,et al.  Spontaneous cytotoxic T-Cell reactivity against indoleamine 2,3-dioxygenase-2. , 2011, Cancer research.

[27]  I. Svane,et al.  Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators. , 2011, Blood.

[28]  A. Mes-Masson,et al.  Androgen-Regulated Expression of Arginase 1, Arginase 2 and Interleukin-8 in Human Prostate Cancer , 2010, PloS one.

[29]  S. Gordon,et al.  Alternative activation of macrophages: an immunologic functional perspective. , 2009, Annual review of immunology.

[30]  G. Riggins,et al.  Diagnosis of Suspicious Thyroid Nodules Using Four Protein Biomarkers , 2006, Clinical Cancer Research.

[31]  V. Bronte,et al.  Regulation of immune responses by L-arginine metabolism , 2005, Nature Reviews Immunology.

[32]  A. Viola,et al.  Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers , 2005, The Journal of experimental medicine.

[33]  F. Brasseur,et al.  Messenger RNA-Electroporated Dendritic Cells Presenting MAGE-A3 Simultaneously in HLA Class I and Class II Molecules1 , 2004, The Journal of Immunology.

[34]  Jennifer Shoemaker,et al.  A preoperative diagnostic test that distinguishes benign from malignant thyroid carcinoma based on gene expression. , 2004, The Journal of clinical investigation.

[35]  N. Enomoto,et al.  Differential gene-expression profiles associated with gastric adenoma , 2004, British Journal of Cancer.

[36]  M. Mielczarek,et al.  Arginase in patients with breast cancer. , 2003, Clinica chimica acta; international journal of clinical chemistry.

[37]  J. M. Fuentes,et al.  Diagnostic performance of arginase activity in colorectal cancer , 2002, Clinical and Experimental Medicine.

[38]  C. Huber,et al.  Transporter (TAP)‐ and proteasome‐independent presentation of a melanoma‐associated tyrosinase epitope , 2000, International journal of cancer.

[39]  S. Cederbaum,et al.  Arginase activity in human breast cancer cell lines: N(omega)-hydroxy-L-arginine selectively inhibits cell proliferation and induces apoptosis in MDA-MB-468 cells. , 2000, Cancer research.

[40]  K Eichmann,et al.  Th1/Th2-regulated expression of arginase isoforms in murine macrophages and dendritic cells. , 1999, Journal of immunology.

[41]  M. Zaborski,et al.  A model system in haematology and immunology: the human monocytic cell line MONO-MAC-1. , 1997, Leukemia research.

[42]  M. Takiguchi,et al.  Molecular cloning of cDNA for nonhepatic mitochondrial arginase (arginase II) and comparison of its induction with nitric oxide synthase in a murine macrophage‐like cell line , 1996, FEBS letters.

[43]  R. Henderson,et al.  HLA-A2.1-associated peptides from a mutant cell line: a second pathway of antigen presentation. , 1992, Science.

[44]  Shigeru Tsuchiya,et al.  Establishment and characterization of a human acute monocytic leukemia cell line (THP‐1) , 1980, International journal of cancer.

[45]  Sylvia Janetzki,et al.  Response determination criteria for ELISPOT: toward a standard that can be applied across laboratories. , 2012, Methods in molecular biology.

[46]  H. Flyger,et al.  High immunogenic potential of p53 mRNA-transfected dendritic cells in patients with primary breast cancer , 2010, Breast Cancer Research and Treatment.